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The principal effectors of the kallikrein-kinin system are plasma and tissue kallikreins, proteases that cleave high molecular weight kininogen to produce bradykinin. Most of the cellular actions of kallikrein (KK) are thought to be mediated by bradykinin, which acts via G protein-coupled B1 and B2 bradykinin receptors on vascular smooth muscle and endothelial cells. Here, we find that primary aortic vascular smooth muscle (VSMC), but not endothelial cells, possess the ability to activate plasma prekallikrein. Surprisingly, exposing vascular smooth muscle cells to prekallikrein leads to activation of the ERK1/2 mitogen-activated protein kinase cascade via a mechanism that requires kallikrein activity, but does not involve bradykinin receptors. In transfected HEK293 cells, we find that plasma kallikrein directly activates G protein-coupled protease-activated receptors (PAR) 1 and 2, which possess consensus kallikrein cleavage sites, but not PAR4. In VSMCs, KK stimulates a disintegrin and metalloprotease (ADAM) 17 activity via a PAR1/2 receptor-dependent mechanism, leading sequentially to release of the endogenous ADAM17 substrates, amphiregulin and tumor necrosis factor-α, metalloproteasedependent transactivation of epidermal growth factor receptors, and metalloprotease-and epidermal growth factor receptor-dependent ERK1/2 activation. These results suggest a novel mechanism of bradykinin-independent kallikrein action that may contribute to the regulation of vascular responses in pathophysiologic states, such as diabetes mellitus.
The kallikrein-kinin system 1 (KKS) plays diverse roles in the regulation of vascular tone, tissue inflammation, coagulation and pain (1) . KKS components are expressed in many tissues and cell lines (2) . Two forms of the KKS exist in humans, the tissue KKS and plasma KKS. Tissue kallikrein (KK) is primarily expressed in the kidney, vascular system, brain and pancreas, where it acts on low molecular weight kininogen (LMWK) to release bradykinin (BK). The plasma KKS is composed of factor XII, prekallikrein (PK) and high molecular weight kininogen (HMWK). It is responsible for the activation of the intrinsic blood clotting pathway (3) (4) (5) . The inactive form of plasma PK is bound to HMWK in the circulation. When this complex assembles along with other components of the KKS on endothelial cell membranes, plasma PK is activated to plasma KK, which cleaves HMWK to release BK both systemically and locally within the vessel wall. The cellular effects of KK are though to reflect primarily the action of BK, a peptide hormone that produces proinflammatory and vasodilatory effects by activating two cell surface G-protein-coupled receptors, the B1 and B2 bradykinin receptors, expressed on vascular endotehilial and vascular smooth muscle cells (VSMC) (6) .
The KKS also interfaces with the reninangiotensin system (RAS; 7). Plasma and tissue KK can convert prorenin to renin, the protease responsible for processing angiotensinogen to angiotensin I. Conversely, angiotensin converting enzyme, the protease responsible for processing angiotensin I to angiotensin II, also cleaves BK to produce its inactive fragment, BK (1) (2) (3) (4) (5) . Thus, factors that enhance the generation of angiotensin II tend to dampen BK signaling. Not surprisingly, given this reciprocal regulation, the KKS and RAS are generally thought to exert opposing effects in the regulation of vascular tone (8) . Angiotensin II, acting via G protein-coupled AT1 and AT2 receptors, causes VSMC constriction and promotes hypertension, whereas under normal physiological conditions, BK stimulates vascular endothelial cells to produce nitric oxide (NO), leading to relaxation of the underlying VSMCs and vasodilation (9, 10) . NO from endothelial cells also inhibits VSMC and renal mesangial cell proliferation (11, 12) . However, in the setting of vascular injury and endothelial denudation, BK can act directly on VSMC to induce their contraction and activate multiple signaling pathways in a manner similar to vasoconstrictors like angiotensin II (13) .
The protease-activated receptors (PARs) are a family of four G-protein-coupled receptors that are activated upon enzymatic cleavage of their Ntermini by specific serine proteases (14, 15) . Each receptor contains an internal 'tethered' ligand buried within its N-terminus that is exposed upon proteolysis. PARs are widely expressed, with PAR1, PAR3 and PAR4 present on platelets, endothelial cells, myocytes and astrocytes, while PAR2 is additionally present on epithelium. PARs are activated or inhibited by a host of proteases from the coagulation cascade, inflammatory cells, and the digestive tract (15) . PAR1, PAR 3 and PAR4 are all activated by thrombin, while PAR2, which is present on intestinal epithelium, is activated by trypsin and tryptase. Depending on their location, PARs regulate diverse processes, including hemostasis, inflammation, cell migration, and pain transmission (16) (17) (18) (19) . Although their physiologic roles have not been well studied, KK and KK-related proteases have recently been implicated as endogenous regulators of PARs in the central nervous system and prostate cancer (20) (21) (22) .
The epidermal growth factor (EGF) receptors, ErbB1-4, comprise a family of classical receptor tyrosine kinases that control cell proliferation and survival via the Ras and phosphatidylinositol-3 kinase/Akt pathways (23) . There are at least eleven endogenous EGF receptor ligands; EGF, transforming growth factor-α, heparin-binding (HB)-EGF, amphiregulin (AR), epiregulin, epigen and neuregulin 1-4, each of which contains a 6 kD domain that is homologous to EGF. All are synthesized as transmembrane precursors that must be cleaved to generate the mature ligand (24) . The processing of EGF family ligands is carried out by metalloprotease-disintegrins of the ADAM family (25) . Unlike most Zinc-binding matrix metalloproteases (MMPs), which are secreted proteins, ADAMs are membraneanchored proteases composed of an extracellular Zn-MMP domain, a single transmembrane domain and a short cytoplasmic tail. Many ADAMs function as 'sheddases' that catalyze intramembrane proteolysis of growth factors, cytokines, receptors and adhesion molecules. Importantly, ADAM-dependent ectodomain shedding is a regulated process, enabling diverse extracellular stimuli to activate EGF receptors by triggering ADAM-dependent release of EGF family ligands (26, 27) .
Substantial evidence supports a role for EGF receptor transactivation in the pathogenesis of vascular injury and atherogenesis. Plasma HB-EGF levels are elevated in coronary artery disease (28) . Expression of pro-HB-EGF, along with ErbB1, and ADAM17 is increased in the shoulder region of atheromas (29, 30) and pathway components can be upregulated by shear stress (31) and endothelial injury (32) . ADAM17, also known as tumor necrosis factor-α (TNF-α) converting enzyme (TACE), is a major sheddase for HB-EGF as well as the pro-inflammatory cytokine TNF-α (29, 33) . Conversely, blockade of EGF receptor activity inhibits intimal hyperplasia in experimental vascular injury (34) . G proteincoupled receptors, like the AT1 receptor (35) , and other stimuli, including lipoprotein remnants, oxidative stress and fluid shear (36) (37) (38) all promote EGF receptor ligand shedding and EGF receptor transactivation.
Here, we describe a novel mechanism whereby plasma KK promotes EGF receptor transactivation and activation of the extracellular signal regulated kinase (ERK) pathway independent of BK. In primary vascular smooth muscle cells, KK acts directly on PAR 1 and 2, stimulating PAR-dependent activation of ADAM17, EGF receptor ligand shedding and EGF receptor transactivation. Given the sometimes opposing and sometimes complementary effects of the RAS and KKS in the vasculature, we speculate that BK-independent effects of KK may play a role in the pathogenesis of vascular disease and therefore present a viable therapeutic target.
MATERIALS AND METHODS cDNA constructs -Full length cDNA clones of PAR1, PAR2 and PAR4 were purchased from University of Missouri -Rolla cDNA Resource Center. cDNAs were amplified by PCR using primers (IDT Technologies, Coralville, IA) designed to introduce Hind3 and EcoR1 sites at the 5' and 3' ends, respectively, and remove the stop codon, and subcloned into the pEGFP-N3 plasmid vector (BD Biosciences, Franklin Lakes, NJ). All sequences were verified by dideoxynucleotide sequencing. Primary cell isolation and culture -Primary rat aortic VSMCs (R-VSMC) were isolated from 75-100 gm Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) as previously described (39 . Immediately upon addition of the reagents, plates were placed in a SPECTRA max 340PC plate reader (Molecular Devices, Sunnyvale, CA) and absorption at 405 nm was measured at 2 min intervals for 2 h. Metalloprotease activity -ADAM activity was measured using two approaches. For the fluorogenic substrate assay, R-VSMCs at 90% confluence in 96 well plates were serum starved for 48 h, after which the medium was replaced with Hank's balanced salt solution containing 20 nM human plasma KK (Enzyme Research Laboratories Inc., South Bend, IN) and 20 µM of the TACE II fluorogenic peptide substrate, MCA-KPLGL-Dpa-AR-NH 2 (EMD Biosciences; Gibbstown, NJ). Fluorescence of the cleaved product, MCA-KPLG, was measured using a Molecular Devices SpectraMax 2 plate reader (Molecular Devices, Sunnyvale, CA) at 324 nm excitation and 400 nm emission wavelengths.
The second method used the Innozyme TACE Activity Kit TM (EMD Biosciences, Gibbstown, NJ). Serum starved R-VSMCs in 10 cm culture dishes were incubated in the presence or absence of 20 nM human plasma KK, lysed as recommended by the manufacturer and normalized for protein content. Equal amounts of sample were loaded into 96 well plates pre-coated with an anti-human TACE monoclonal antibody, incubated for 2 h at room temperature, and washed, after which the activity of immobilized ADAM17 was measured using MCA-KPLGL-Dpa-AR-NH2 as above. Protein immunoblotting -Endogenous phosphoproteins were detected by immunoblotting whole cell lysates using phosphorylation site-specific IgG. Serum starved R-VSMC in 6-well plates were stimulated at 37 °C as described in the figure legends, lysed with 1X hypotonic sample buffer (Invitrogen, Carlsbad, CA), sonicated, boiled, resolved by 4-12% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Invitrogen, Carlsbad, CA), and transferred to polyvinylidine difluoride membrane (Millipore, Billerica, MA). Phosphorylated ERK1/2 was detected using rabbit polyclonal anti-phospho-ERK1/2 IgG (Cell Signaling Technology Inc., Beverly, MA) with horseradish peroxidaseconjugated goat anti-rabbit IgG secondary antibody (Jackson Immuno Research Laboratories Inc., West Grove, PA). Phosphorylated JNK1/2 was detected using rabbit polyclonal anti-phospho-JNK1/2 IgG (Cell Signaling Technology Inc., Beverly, MA). Phosphorylated EGF receptor was detected using rabbit polyclonal anti-ErbB1 phospho-Tyr 1068 IgG (Cell Signaling Technology Inc., Beverly, MA). Total ERK1/2, measured to confirm equal loading of whole cell lysate samples, was detected using polyclonal anti-ERK1/2 IgG (Upstate Biotechnology Inc., Waltham, MA).
Immune complexes were visualized on X-ray film by enzyme-linked chemiluminescence. Multiple exposures were made of each immunoblot and band intensities on optimally exposed films were quantified using a Fluor-S MultiImager (Bio-Rad, Irvine, CA). ADAM17 ligand shedding -H-VSMCs at 90% confluence in 10 cm culture dishes were serum starved for 24 h, after which the medium was replaced with 7 ml of medium containing 0.5% fetal bovine serum and monolayers were incubated for 3 hr, with or without 20 nM human plasma KK. Conditioned medium was collected and concentrated using iCON TM Concentrator 7ml/9K tubes (Pierce, Rockford, IL) centrifuged at 4000 rpm at 4°C for 1 h. Aliquots of concentrated medium were mixed with 2X sample buffer and resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Amphiregulin and TNFα release were quantified by immunoblotting using rabbit polyclonal anti-amphiregulin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or anti-TNFα IgG (Chemicon International, Inc., Billerica, MA) with horseradish peroxidaseconjugated goat anti-rabbit IgG secondary antibody. Confocal microscopy -To visualize GFP-PAR1-4 internalization, HEK293 cells were transfected with plasmids encoding GFP-tagged PAR-1, PAR-2 or PAR-4 as described. Transfected cells were plated onto collagen coated 35 mm glass bottom culture dishes (MatTek Co., Ashland, MA), serum starved overnight, stimulated as described in the figure legends, washed with Hank's balanced salt solution, and fixed with freshly prepared 4% paraformaldehyde for 30 min at room temperature. For co-staining, cells were permeabilized with 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO) in phosphate buffered saline for 5 min, after which nonspecific binding sites were blocked with 3% serum in phosphate buffered saline for 1 h. Cells were labelled for 1 h at room temperature in blocking buffer containing 3-4 µg/ml mouse monoclonal anti-early endosomal antigen 1 (EEA1; BD Transduction Laboratories, Franklin Lakes, NJ), washed, and then incubated with a 1:300 dilution of goat anti-mouse AlexaFluor-568 (Invitrogen, Carlsbad, CA), also in blocking buffer for 1 h at room temperature. Nuclear DNA was stained using 4',6-diamidino-2-phenylindole (DAPI; Invitrogen, Carlsbad, CA).
Confocal images were captured on a Zeiss LSM510 laser scanning microscope using a Zeiss 63X 1.4 numerical aperture water immersion lens using excitation 488 nm, emission 505-530 nm; and, excitation 543 nm, emission 560-615 nm filter sets. Images were analyzed using MetaMorph software (Molecular Devices, Sunnyvale, CA). At least ten individual cells per condition from three separate experiments were analyzed. For each image, regions of interest were manually defined encompassing either the entire cell (total GFP fluorescence) or the region of the cell excluding the plasma membrane (cytosolic GFP fluorescence). Data were then expressed as the ratio of cytosolic GFP fluorescence to total fluorescence x 100% (% internalized receptor). RESULTS Plasma prekallikrein mediates bradykininindependent activation of the ERK1/2 cascade in primary vascular smooth muscle, but not endothelial, cells. To determine whether vascular smooth muscle or endothelial cells are able to activate plasma PK, we assayed KK activity in R-VSMC, H-VSMC, HUVEC and HAEC in cultures incubated with 100 nM human plasma PK. As shown in Figure 1 , VSMC from either source were able to activate plasma PK, leading to cleavage of the fluorogenic KK substrate, S2302. In contrast umbilical vein and aortic endothelial cells were unable to activate PK in vitro.
As shown in Figure 2A , R-VSMC exposed to plasma PK at physiologic concentrations (40) exhibited a time and dose dependent increase in ERK1/2 phosphorylation that paralleled the time course of PK activation. The effect required KK proteolytic activity, since it was blocked by the KK inhibitor, aprotinin (data not shown). Since the PK-induced ERK1/2 response occurred in the absence of an exogenous source of kininogen, we hypothesized that it resulted from proteolysis of an endogenous VSMC substrate. To exclude a role for BK receptors, we tested whether the BK receptor antagonist, HOE140, affected KKinduced ERK1/2 activation. As shown in Figure  2B , HOE140 had no effect on KK-stimulated ERK1/2 phosphorylation at a concentration sufficient to block the effect of exogenouslysupplied BK. Plasma kallikrein activates PAR1 and PAR2 leading to PAR-dependent ADAM activation. Plasma KK is a trypsin fold serine protease that cleaves substrates following Arg or Lys residues (41) . As shown in Figure 3A , the tethered ligand buried within the N-terminus of PARs is bounded by Arg or Lys, and almost all known PAR activation is carried out by trypsin fold serine proteases. Moreover, several kallikrein-related peptidases have been shown to activate PARs with variable specificity (42) (43) (44) , and kallikrein-related peptidase 4 was recently reported to activate PAR1 and PAR2, but not PAR4, in prostate cancer cells (21) . To test whether plasma KK activates PARs, we assayed for KK-dependent internalization of GFP-tagged PAR1, PAR2 and PAR4 expressed in HEK293 cells. Activation-dependent internalization is a characteristic feature of most GPCRs (45) . As shown in Figure 3B , in vehicle treated cells GFP-PAR1 was found primarily on the plasma membrane, with a lesser amount of GFP fluorescence, probably representing nascent GFPtagged receptors, present in the cytsol. Exposure to either thrombin or KK for 15 min caused a striking loss of GFP-PAR1 from the plasma membrane and accumulation within cytosolic puncta that partially colocalized with the early endosomal marker EAA1. Figure 3C compares the ability of KK to stimulate internalization of GFP-PAR1, -PAR2 and -PAR4. GFP-PAR1 and GFP-PAR4 moved from the plasma membrane into the cytosol upon exposure to a known activator, thrombin, consistent with activationdependent receptor internalization. GFP-PAR2 similarly internalized when exposed to trypsin, an endogenous activator of PAR2. When exposed to plasma KK, GFP-PAR1 and GFP-PAR2, but not GFP-PAR4, internalized, suggesting that plasma KK activates PARs with substrate specificity similar to that reported for kallikrein-related peptidase 4. Figure 3D presents these results quantitatively.
As shown in Figure 4A , exposing R-VSMCs to plasma KK produced a dose-dependent increase in matrix metalloprotease activity assayed using the ADAM10/ADAM17-specific fluorogenic substrate, KPLGL-Dpa-AR-NH 2 . As shown in Figure   4B , repeating the experiment using the ADAM17/TACE-specific Innozyme TACE activity assay confirmed that the increase was due, at least in part, to KK-dependent activation of ADAM17. The KK effect was detectable within 5 min of exposure and persisted for at least 15 min.
Since ADAM17 is regulated by multiple stimuli, including many G protein-coupled receptors (26, 27) , we next tested whether there was a link between KK-dependent PAR activation and its activation of ADAM17 in R-VSMC. For these experiments, R-VSMCs were preincubated in the presence of PAR1 or PAR2 antagonist peptides prior to exposing the cells to KK. Since these peptides are related to the internal PAR1/2 ligand sequence, we first had to exclude the possibility that they would also behave as pseudosubstrate inhibitors of plasma KK. As shown in Figure 4C , neither peptide had any effect upon KK activity when assayed in a cell free system. Similarly, neither peptide interfered with the ability of recombinant ADAM17/TACE to cleave its fluorogenic substrate, KPLGL-Dpa-AR-NH 2 , in a cell free assay (data not shown). However, as shown in Figure 4D , the PAR1 and PAR2 antagonist peptides blocked KK-induced ADAM activation in R-VSMCs, suggesting that KK cleavage of PARs occurs upstream of ADAM activation. The two inhibitors in combination were somewhat more effective that either alone, however the difference was not statistically significant. Plasma kallikrein stimulates ADAM-dependent amphiregulin release and EGF receptor transactivation in primary aortic vascular smooth muscle. ADAMs are known to play a key role in the regulated shedding of at least six of the known EGF family ligands, transforming growth factor-α, EGF, HB-EGF, betacellulin, epiregulin and AR (46) . Of these, HB-EGF and AR have been implicated in the control of VSMC proliferation and development of vascular disease (28) (29) (30) (47) (48) (49) . To determine if the KK-induced increase in ADAM activity increased VSMC shedding of EGF family growth factors, we looked for the presence of AR and HB-EGF in the culture medium after KK exposure. Because speciesspecific antibodies recognizing rat AR and HB-EGF are not available, we employed primary H-VSMC for these experiments. As shown in Figure  5A , KK exposure increased the amount of shed AR compared to vehicle treated control cells. As shown in Figure 5B , KK-stimulated AR release was ADAM-dependent, since it was sensitive to the broad-spectrum MMP inhibitor GM6001. Although we were unable to detect HB-EGF shedding in response to plasma KK (data not shown), we did observe increased shedding of another ADAM17/TACE substrate, TNFα, consistent with the results of our direct assay of ADAM17/TACE activity. As shown in Figure  6A , GM6001 had no effect on KK activity in a cell free assay, confirming that the inhibition of KKinduced AR shedding did not result from direct inhibition of plasma KK. As shown in Figure 6B , we observed a rapid three-fold increase in EGF receptor autophosphorylation (ErbB1 pY 1068 ) in R-VSMC upon KK treatment that was sensitive to GM6001, consistent with ADAM-dependent EGF receptor ligand shedding in KK-treated cells.
Kallikrein-stimulated ERK1/2 and JNK activity in primary aortic vascular smooth muscle is partially ADAM-and EGF receptor-dependent.
EGF receptor transactivation contributes to ERK1/2 activation by diverse stimuli, including many G protein-coupled receptors (26, 27) .
To test whether transactivation was involved in KKinduced activation of the ERK1/2 and JNK cascades in primary VSMC, we determined whether the activation of these pathways by PK or KK in R-VSMC was sensitive to inhibition by GM6001 or the EGF receptor kinase inhibitor, AG1478. As shown in Figure 7A , 15 min exposure to either PK or KK produced ERK1/2 activation that was significantly inhibited in the presence of GM6001. Figure 7B illustrates similar effects on PK-and KK-induced JNK1/2 phosphorylation, implicating MMP-dependent ectodomain shedding in both signals. As shown in Figure 7C , KK-induced ERK1/2 activation was substantially, but incompletely, inhibited by AG1478 at a concentration sufficient to completely block ERK1/2 activation by exogenously-supplied EGF. These results indicate that MMP-dependent EGF receptor transactivation plays a significant role in the VSMC response to KK exposure. The incomplete effect of GM6001 and AG1478 indicates that other pathways, possibly also mediated via KK-activated PAR1/2, contribute to ERK1/2 activation, as has been shown for other G protein-coupled receptors (50) . DISCUSSION The RAS and KKS constitute an interlocking signaling network involved in the regulation of vascular function (7) (8) (9) (10) . Coordinate regulation is achieved through shared pathway components. Plasma and tissue KK, which generate BK from HMWK and LMWK, respectively, also convert prorenin to renin, enhancing RAS activity, while angiotensin converting enzyme, the source of angiotenisn II, also cleaves BK to an inactive fragment. The principal effectors of the two systems, angiotensin II and BK, exert opposing effects on vascular tone, with angiotensin II directly promoting VSMC contraction and BK indirectly causing vasodilation through BK receptor-mediated NO generation by vascular endothelial cells. Despite the generally salutary effects of BK, it is clear that dysregulation of the KKS is associated with progression of the vascular and renal complications of diabetes mellitus (40) . In the setting of endothelial denudation, BK can act directly on B1 and B2 bradykinin receptors expressed by VSMC to promote vasoconstriction in a manner similar to angiotensin II (13) . The complex roles of the KKS in health and disease and its potential as a therapeutic target underscore the importance of understanding its mechanisms of action in vascular tissue.
Under normal physiologic conditions VSMC are not directly exposed to plasma PK due to the presence of an intact endothelial barrier. As we demonstrate, endothelial cells lack the ability to activate PK in the absence of factor XIIa generated through activation of the intrinsic clotting system (1-3). In contrast, we find that VSMCs, which could be exposed to PK in the setting of vascular injury and endothelial denudation, do not require exogenous clotting cascade factors to generate KK. Activation of plasma PK by VSMC does involve proteolysis, since incubation of PK with VSMC leads to the generation of cleaved PK fragments that is identical to those produced when PK is activated by factor XIIa in a cell-free system (data not shown). However the identity of the VSMC protease(s) responsible for PK activation remains to be determined. Unlike endothelial cells, activation of PK by VSMC also does not require HMWK, which mediates the binding of PK to endothelial cell membranes, indicating that the mechanism of PK binding, as well as its cleavage/activation by VSMC is distinct from that employed by endothelial cells.
Our data suggest that PK activation by VSMC initiates a cascade of signaling events leading to EGF receptor transactivation and activation of the ERK1/2 and JNK cascades that, ironically, involves neither BK or B1/B2 receptors. As depicted schematically in Figure 8 , PK binding to an as yet unknown PK activator on the surface of VSMCs generates KK. Among the substrates cleaved by KK are the N-termini of PAR1/2. One consequence of PAR activation is increased ADAM activity, specifically including ADAM17/ TACE, which acts on cell surface EGF receptor ligand precursors, including AR, to transactivate EGF receptors and on unprocessed TNFα to enhance its release. While it is likely that in vivo activation of PK on VSMC also leads to BK production and B1/B2 receptor activation, our results demonstrate a direct role for plasma KK in the activation of PAR1/2 and stimulation of pathways involved in the control of cell proliferation, apoptosis, and inflammation.
Like BK receptors, PARs are expressed on both endothelial cells and VSMCs. Endothelial cells primarily express PAR1, although PAR2, PAR3 and PAR4 are also present (16, 51, 52) . In normal arteries thrombin can trigger either endothelium-dependent relaxation (53, 54) or endothelium-dependent contraction (55) . The dominant effect varies between vascular beds, with human and porcine coronary arteries undergoing vasodilation (54, 56) , whereas in porcine renal interlobular arteries thrombin induces a biphasic effect resulting from initial NO-dependent relaxation followed by calcium-dependent contraction (55) . Although direct thrombininduced contraction of canine coronary arteries has been reported, VSMC normally express only low levels of PAR1 (57) . VSMC expression of PAR1 and PAR2 is upregulated, however, under pathophysiologic conditions, for example following balloon injury (58, 59) or in human atherosclerotic lesions (60, 61) , and is associated with an exaggerated contractile response to thrombin in vitro (62) . Thrombin stimulates VSMC proliferation, hypertrophy and migration in vitro (63, 64) through Ca 2+ and PKC-dependent effects on the expression of egr-1, c-fos, c-jun, junB, FosB and fra-1 (65, 66) . Since vascular injury would both expose VSMC to plasma PK and upregulate PAR1/2 expression, our findings suggest that PAR1/2 activation by VSMCactivated plasma KK may exacerbate the vascular injury response.
One consequence we find of KK-mediated PAR1/2 activation in VSMCs is activation of ADAM family MMPs, notably ADAM17/TACE. PAR-dependent ADAM activation is associated with increased AR and TNFα secretion, MMPdependent EGF receptor activation, and EGF receptor-dependent activation of the ERK1/2 and JNK pathways. ADAM17 is the major sheddase for HB-EGF and AR in VSMC. As with the PARs, expression of ADAM17, along with other components of the EGF receptor signaling network, is upregulated in the setting of endothelial injury, shear stress and atherosclerosis (29) (30) (31) (32) (33) . Transactivation of EGF receptors, triggered by diverse stimuli, including G proteincoupled receptor activation, oxidative stress and fluid shear, has been shown to play an important role in the vascular injury response, promoting VSMC hypertrophy and hyperplasia, as well as fibroblast proliferation (34) (35) (36) (37) (38) .
Whereas in normal arteries an intact endothelium shields underlying VSMCs from exposure to plasma PK, and endothelial cell BK receptors and PARs, on balance, produce vasodilatory responses that oppose RAS-mediated vasoconstriction, loss of endothelial integrity may set up a 'perfect storm' wherein these normally protective factors exacerbate vascular injury and contribute to disease progression. With both PAR1/2 and EGF receptor pathway components upregulated, VSMC are poised to respond to circulating factors in a manner that promotes vascular injury. Our data suggest that plasma PK, activated on the surface of exposed VSMC, may be one such factor, not only generating BK, but causing direct PAR1/2 activation, EGF receptor transactivation, and the release of proinflammatory cytokines. As such, KK, which also increases RAS activity by activating prorenin, may be an attractive therapeutic target for the treatment of vascular disease in high risk settings. 1 The abbreviations used are: ADAM, a disintegrin and metalloprotease; AR, amphiregulin; BK, bradykinin; EAA1, early endosomal antigen 1; EGF, epidermal growth factor; ERK1/2, extracellular signal-regulated kinases 1 and 2; GFP, green fluorescent protein; HAEC, human aortic endothelial cell; HB, heparin-binding; HMWK, high molecular weight kininogen; HUVEC, human umbilical vein endothelial cell; JNK, c-jun N-terminal kinase; KK, kallikrein; KKS, kallikrein-kinin system; LMWK, low molecular weight kininogen; MMP, matrix metalloprotease; NO, nitric oxide; PAR, proteaseactivated receptor; PK, prekallikrein; RAS, renin-angiotensin system; TACE, TNFα converting enzyme; TNFα, tumor necrosis factor-α; VSMC, vascular smooth muscle cell. FIG 1. Activation of plasma prekallikrein in primary vascular smooth muscle, but not endothelial,  cells . Serum deprived R-VSMC, H-VSMC, HUVEC or HAEC in 96-well plates were incubated with 100 nM human PK in the presence of the chromogenic substrate for plasma KK, S2302 (0.6 mM) and KK activity was quantified as change in absorption at 405 nm measured at 2 min intervals over 2 h. Data shown are from one of three experiments that produced comparable results. A, Serum deprived R-VSMCs in 6-well plates were preincubated in the presence or absence of GM6001 (10 µM) for 15 min prior to treatment with 200 nM PK or 20 nM plasma KK for 15 min. ERK1/2 phosphorylation was determined by immunoblotting whole cell lysates as described. Total cell ERK1/2 was blotted as a control for equal protein loading. B, Serum deprived R-VSMCs were preincubated in the presence or absence of GM6001 for 15 min prior to treatment with 200 nM PK or 20 nM plasma KK for 15 min. JNK phosphorylation was determined by immunoblotting whole cell lysates and total cell JNK was blotted as a control for equal protein loading. C, Serum deprived R-VSMCs were preincubated in the presence or absence of AG1478 (100 nM) for 15 min prior to treatment with 10 nM EGF or 20 nM plasma KK for 15 min. ERK1/2 phosphorylation was determined by immunoblotting whole cell lysates and total cell ERK1/2 was blotted as a control for equal protein loading. Each bar graph represents the Mean ± S.E.M. for three separate experiments. * greater than untreated control, p < 0.05; † less than stimulated in the absence of inhibitor, p < 0.05. 
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